VIRIDIAN THERAPEUTICS ORS INC (VRDN) — insider trading
Health Care · NASDAQ
VIRIDIAN THERAPEUTICS ORS INC (VRDN) has 22 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 2 open-market sales among the most recent 22 (latest 2026-08-19).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | Tousignant Jennifer | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-08-19 | Tousignant Jennifer | Officer (Chief Legal Officer) | Open-market sale | 10,000 | $24.50 | $245.0K | Form 4 |
| 2026-08-19 | Tousignant Jennifer | Officer (Chief Legal Officer) | Option exercise / conversion | 10,000 | $14.41 | $144.1K | Form 4 |
| 2026-08-19 | Tousignant Jennifer | Officer (Chief Legal Officer) | Open-market sale | 4,212 | $24.50 | $103.2K | Form 4 |
| 2026-08-14 | Tripuraneni Radhika | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-08-14 | Tripuraneni Radhika | Officer (Chief Medical Officer) | Option exercise / conversion | 40,000 | $13.21 | $528.4K | Form 4 |
| 2026-07-01 | Morris Arlene | Director | Grant / award / vesting (derivative) | 32,341 | — | $0 | Form 4 |
| 2026-07-01 | Kiselak Tomas | Director | Grant / award / vesting (derivative) | 32,341 | — | $0 | Form 4 |
| 2026-07-01 | Gheuens Sarah | Director | Grant / award / vesting (derivative) | 32,341 | — | $0 | Form 4 |
| 2026-07-01 | Moses Jennifer K. | Director | Grant / award / vesting (derivative) | 32,341 | — | $0 | Form 4 |
| 2026-07-01 | Ajer Jeffrey Robert | Director | Grant / award / vesting (derivative) | 32,341 | — | $0 | Form 4 |
| 2026-07-01 | CAIN CHRISTOPHER W. | Director | Grant / award / vesting (derivative) | 32,341 | — | $0 | Form 4 |
| 2026-05-11 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P. | Director, 10% owner | Open-market purchase | 1,176,470 | $17.00 | $20.00M | Form 4 |
| 2026-03-03 | Mahoney Stephen F. | Director, Officer (President and CEO) | Shares withheld for taxes / exercise cost | 7,408 | $30.19 | $223.6K | Form 4/A |
| 2026-03-03 | Tousignant Jennifer | Officer (Chief Legal Officer) | Shares withheld for taxes / exercise cost | 1,675 | $30.19 | $50.6K | Form 4/A |
| 2026-03-03 | Beetham Thomas W. | Officer (Chief Operating Officer) | Shares withheld for taxes / exercise cost | 3,048 | $30.19 | $92.0K | Form 4/A |
| 2026-03-03 | Harmon Seth | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 2,031 | $30.19 | $61.3K | Form 4/A |
| 2026-03-03 | Tousignant Jennifer | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 5,169 | — | $0 | Form 4 |
| 2026-03-03 | Tousignant Jennifer | Officer (Chief Legal Officer) | Shares withheld for taxes / exercise cost | 1,724 | $29.32 | $50.5K | Form 4 |
| 2026-03-03 | Tousignant Jennifer | Officer (Chief Legal Officer) | Option exercise / conversion | 5,169 | — | — | Form 4 |
| 2026-03-02 | Tousignant Jennifer | Officer (Chief Legal Officer) | Grant / award / vesting (derivative) | 23,850 | — | $0 | Form 4 |
| 2026-03-02 | Tousignant Jennifer | Officer (Chief Legal Officer) | Grant / award / vesting (derivative) | 119,300 | — | $0 | Form 4 |
Ask the chat about VRDN's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: VIRIDIAN THERAPEUTICS ORS INC (VRDN).
Last updated 2026-08-19 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.